Oral 65 High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/R+dasabuvir+/-Ribavirin: Integrated Safety and Efficacy Analysis
Author Insight from Nancy Reau, MD, Chief, Section of Hepatology, Associate Director, Solid Organ Transplantation, Rush University Medical Center
What’s new here and important for clinicians?
Traditionally baseline characteristics, especially race, have led clinicians to characterize HCV patients as likely or unlikely to achieve a cure. The all-oral combination of ombitasvir/paritaprevir/r+dasabuvir+/-ribavirin has allowed treatment efficacy to overcome these hurdles.
What do patients need to know?
All-oral therapy for HCV is highly effective. If treatment was deferred in the past due to a high risk of failure, they should re-consider treatment.
Author Contact Nancy Reau, MD, Chief, Section of Hepatology, Associate Director, Solid Organ Transplantation, Rush University Medical Center
Media Interview Requests:
To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000.